A phase 1 study of AVC-203, a dual-targeting CD19/CD20 allogeneic CAR-T, in patients with B-cell malignancies

In October 2026, TAP made a strategic investment in AvenCell Therapeutics to support the clinical development of investigational, allogeneic, or “off-the-shelf,” CAR-T cell therapy for people with relapsed or refractory blood cancers. 

AvenCell Therapeutics is a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies for blood cancers. The company’s technology combines healthy donor-derived, gene-edited T cells with a switchable targeting system designed to give physicians greater control over CAR-T activity. Unlike traditional CAR-T therapies that are manufactured individually from a patient's own cells, AvenCell's approach is designed to provide an off-the-shelf therapy that can be available when patients need treatment.

TAP support will help advance the Phase 1b expansion of AVC-201 and generate additional evidence about its safety, durability of response, blood-count recovery, and potential role for patients with AML.

AvenCell is also developing AVC-203, an investigational allogeneic CAR-T therapy targeting CD19 and CD20 for patients with B-cell malignancies, including B-cell lymphomas (NCT07284433). AVC-203 is earlier in clinical development and provides an opportunity to evaluate AvenCell's allogeneic CAR-T platform across another group of blood cancers.